Genetic and non‐genetic drug resistance: Darwin or Lamarck?
Drug resistance represents a major limitation to the long‐term efficacy of anti‐cancer treatments. The commonly accepted view is that the selection of inheritable genetic mechanisms governs the development of secondary resistance. However, compelling evidence suggests an important role for adaptive...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13601 |
| _version_ | 1797320913319886848 |
|---|---|
| author | Mariangela Russo |
| author_facet | Mariangela Russo |
| author_sort | Mariangela Russo |
| collection | DOAJ |
| description | Drug resistance represents a major limitation to the long‐term efficacy of anti‐cancer treatments. The commonly accepted view is that the selection of inheritable genetic mechanisms governs the development of secondary resistance. However, compelling evidence suggests an important role for adaptive cell plasticity and non‐genetic mechanisms in the development of therapy resistance. The two phenomena are not mutually exclusive and the interplay between genetic and non‐genetic mechanisms may affect tumor evolution during treatment. A broader characterization of the genetic and non‐genetic mechanisms of drug resistance may pave the way for more precise and effective therapeutic strategies to overcome resistance. |
| first_indexed | 2024-03-08T04:49:56Z |
| format | Article |
| id | doaj.art-b22c5c49e04042bb8d19f823b8c005b9 |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-03-08T04:49:56Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-b22c5c49e04042bb8d19f823b8c005b92024-02-08T06:47:52ZengWileyMolecular Oncology1574-78911878-02612024-02-0118224124410.1002/1878-0261.13601Genetic and non‐genetic drug resistance: Darwin or Lamarck?Mariangela Russo0Department of Oncology, Molecular Biotechnology Center University of Torino ItalyDrug resistance represents a major limitation to the long‐term efficacy of anti‐cancer treatments. The commonly accepted view is that the selection of inheritable genetic mechanisms governs the development of secondary resistance. However, compelling evidence suggests an important role for adaptive cell plasticity and non‐genetic mechanisms in the development of therapy resistance. The two phenomena are not mutually exclusive and the interplay between genetic and non‐genetic mechanisms may affect tumor evolution during treatment. A broader characterization of the genetic and non‐genetic mechanisms of drug resistance may pave the way for more precise and effective therapeutic strategies to overcome resistance.https://doi.org/10.1002/1878-0261.13601drug resistanceepigeneticgenetictumor evolution |
| spellingShingle | Mariangela Russo Genetic and non‐genetic drug resistance: Darwin or Lamarck? Molecular Oncology drug resistance epigenetic genetic tumor evolution |
| title | Genetic and non‐genetic drug resistance: Darwin or Lamarck? |
| title_full | Genetic and non‐genetic drug resistance: Darwin or Lamarck? |
| title_fullStr | Genetic and non‐genetic drug resistance: Darwin or Lamarck? |
| title_full_unstemmed | Genetic and non‐genetic drug resistance: Darwin or Lamarck? |
| title_short | Genetic and non‐genetic drug resistance: Darwin or Lamarck? |
| title_sort | genetic and non genetic drug resistance darwin or lamarck |
| topic | drug resistance epigenetic genetic tumor evolution |
| url | https://doi.org/10.1002/1878-0261.13601 |
| work_keys_str_mv | AT mariangelarusso geneticandnongeneticdrugresistancedarwinorlamarck |